Possibilities of targeted therapy for myelofibrosis: Moscow experience
Background. For many years the primary aim of treatment strategy for ph-negative myeloproliferative neoplasms has been to restrain disease progression, with lasting relief and management of symptoms to improve patients’ quality of life. Generally, this did not lead to a significant increase in life...
Saved in:
| Main Authors: | O. Yu. Vinogradova, M. M. Pankrashkina, D. I. Shikhbabaeva, M. V. Chernikov, A. L. Neverova, V. L. Ivanova, E. A. Nikitin, E. V. Usikova, V. V. Ptushkin |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-11-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/593 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Molecular markers as possible efficacy predictors of targeted therapy for myelofibrosis: single-center study
by: O. Yu. Vinogradova, et al.
Published: (2023-12-01) -
Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study
by: O. Yu. Vinogradova, et al.
Published: (2024-09-01) -
Targeted Therapy of Myelofibrosis
by: OYu Vinogradova, et al.
Published: (2017-10-01) -
Melanoma during Ruxolitinib Treatment for Myelofibrosis
by: Lingzhi Zhong, et al.
Published: (2025-07-01) -
Combination therapy with ruxolitinib plus low-dose cytarabine or mercaptopurine in patients with blast-phase myelofibrosis
by: M. S. Fominykh, et al.
Published: (2016-08-01)